Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ONTY's Cash to Debt is ranked higher than
91% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ONTY: No Debt )
ONTY' s 10-Year Cash to Debt Range
Min: 5.92   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ONTY's Interest Coverage is ranked higher than
81% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONTY: No Debt )
ONTY' s 10-Year Interest Coverage Range
Min: 1060.29   Max: 9999.99
Current: No Debt

1060.29
9999.99
F-Score: 1
Z-Score: 6.28
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -54.17
ONTY's ROE (%) is ranked higher than
61% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. ONTY: -54.17 )
ONTY' s 10-Year ROE (%) Range
Min: -169.23   Max: 35.83
Current: -54.17

-169.23
35.83
ROA (%) -49.85
ONTY's ROA (%) is ranked higher than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ONTY: -49.85 )
ONTY' s 10-Year ROA (%) Range
Min: -108.78   Max: 29.72
Current: -49.85

-108.78
29.72
ROC (Joel Greenblatt) (%) -2432.04
ONTY's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. ONTY: -2432.04 )
ONTY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10718.56   Max: 856.06
Current: -2432.04

-10718.56
856.06
EBITDA Growth (%) 2.30
ONTY's EBITDA Growth (%) is ranked higher than
82% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ONTY: 2.30 )
ONTY' s 10-Year EBITDA Growth (%) Range
Min: -60   Max: 29.6
Current: 2.3

-60
29.6
EPS Growth (%) 2.20
ONTY's EPS Growth (%) is ranked higher than
84% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ONTY: 2.20 )
ONTY' s 10-Year EPS Growth (%) Range
Min: -60.4   Max: 28.7
Current: 2.2

-60.4
28.7
» ONTY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ONTY Guru Trades in Q2 2013

Jean-Marie Eveillard 1,295,499 sh (+547.75%)
Murray Stahl 32,333 sh (+14.12%)
Andreas Halvorsen Sold Out
Jim Simons 496,100 sh (-50.57%)
» More
Q3 2013

ONTY Guru Trades in Q3 2013

Jean-Marie Eveillard 2,275,287 sh (+75.63%)
Jim Simons 707,362 sh (+42.58%)
Murray Stahl 32,333 sh (unchged)
» More
Q4 2013

ONTY Guru Trades in Q4 2013

Paul Tudor Jones 39,902 sh (New)
Jean-Marie Eveillard 2,624,987 sh (+15.37%)
Murray Stahl 32,333 sh (unchged)
Jim Simons 156,700 sh (-77.85%)
» More
Q1 2014

ONTY Guru Trades in Q1 2014

George Soros 89,600 sh (New)
Jean-Marie Eveillard 2,724,987 sh (+3.81%)
Murray Stahl 32,333 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 30,757 sh (-22.92%)
» More
» Details

Insider Trades

Latest Guru Trades with ONTY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 New Buy$1.71 - $3.89 $ 3.2922%89600
Jean-Marie Eveillard 2013-09-30 Add 75.63%0.01%$1.59 - $2.18 $ 3.2988%2275287
Jean-Marie Eveillard 2013-06-30 Add 547.75%0.01%$1.57 - $2.63 $ 3.2954%1295499
Jean-Marie Eveillard 2013-03-31 New Buy$1.86 - $2.35 $ 3.2957%200000
Jean-Marie Eveillard 2012-03-31 Sold Out 0.0033%$4.16 - $8.96 $ 3.29-48%0
Jean-Marie Eveillard 2011-12-31 Add 33.33%$5.84 - $8.25 $ 3.29-52%100000
Jean-Marie Eveillard 2011-09-30 Reduce -66.67%0.01%$5.95 - $10.2 $ 3.29-56%75000
Jean-Marie Eveillard 2011-06-30 New Buy0.01%$3.8 - $9.43 $ 3.29-43%225000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.50
ONTY's P/B is ranked higher than
83% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. ONTY: 3.50 )
ONTY' s 10-Year P/B Range
Min: 0.75   Max: 23.93
Current: 3.5

0.75
23.93
EV-to-EBIT -3.19
ONTY's EV-to-EBIT is ranked lower than
52% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ONTY: -3.19 )
ONTY' s 10-Year EV-to-EBIT Range
Min: 0.2   Max: 14.2
Current: -3.19

0.2
14.2
Current Ratio 18.13
ONTY's Current Ratio is ranked higher than
95% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ONTY: 18.13 )
ONTY' s 10-Year Current Ratio Range
Min: 1.67   Max: 36.71
Current: 18.13

1.67
36.71
Quick Ratio 18.13
ONTY's Quick Ratio is ranked higher than
96% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ONTY: 18.13 )
ONTY' s 10-Year Quick Ratio Range
Min: 0.95   Max: 36.71
Current: 18.13

0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.20
ONTY's Price/Net Cash is ranked higher than
93% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. ONTY: 4.20 )
ONTY' s 10-Year Price/Net Cash Range
Min: 1.03   Max: 55.33
Current: 4.2

1.03
55.33
Price/Net Current Asset Value 4.20
ONTY's Price/Net Current Asset Value is ranked higher than
93% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. ONTY: 4.20 )
ONTY' s 10-Year Price/Net Current Asset Value Range
Min: 0.95   Max: 30.13
Current: 4.2

0.95
30.13
Price/Tangible Book 3.60
ONTY's Price/Tangible Book is ranked higher than
87% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. ONTY: 3.60 )
ONTY' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 81
Current: 3.6

0.84
81
Price/Median PS Value 1.10
ONTY's Price/Median PS Value is ranked higher than
54% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ONTY: 1.10 )
ONTY' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 27.27
Current: 1.1

0.01
27.27
Forward Rate of Return (Yacktman) -14.97
ONTY's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. ONTY: -14.97 )
ONTY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -125.6   Max: -15.6
Current: -14.97

-125.6
-15.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:3O6.Germany
Oncothyreon, Inc., was incorporated in 1985 in Canada under the name Biomira Inc., or Biomira. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. The company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The company's cancer vaccine product candidate, L-BLP25 formerly known as Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted, license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of L-BLP25. The Company is also developing ONT-701, a preclinical pan-inhibitor of the B-cell lymphoma-2, or Bcl-2, family of anti-apoptotic proteins. The company's pipeline of product candidates is comprised of cancer vaccines and small molecules. Its cancer vaccines attack cancer cells by stimulating the immune system, while its small molecule product candidates inhibit critical cancer-related pathways. The resulting product pipeline provides it with opportunities to diversify risk, develop new therapies and establish strategic partnerships. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.
» More Articles for ONTY

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
pro-longs life Jul 30 2011 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
cooldecency99 note on ONTY May 01 2010 
creiter note on ONTY Jan 03 2010 


More From Other Websites
ONCOTHYREON INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Jun 10 2014
Can the Rally in Oncothyreon (ONTY) Shares Continue? Jun 06 2014
ONCOTHYREON INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Jun 02 2014
Oncothyreon Announces Presentation of ONT-10 Data at ASCO Annual Meeting Jun 02 2014
Oncothyreon Collaborates with Celldex May 30 2014
Oncothyreon and Celldex to collaborate for clinical trial of ONT-10 and Varlilum May 29 2014
Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical... May 29 2014
Oncothyreon to Present at Jefferies 2014 Global Healthcare Conference May 28 2014
ONCOTHYREON INC. Financials May 09 2014
Oncothyreon's CEO Discusses Q1 2014 Results - Earnings Call Transcript May 01 2014
Oncothyreon Inc . Discusses Q1 2014 Results (Webcast) May 01 2014
ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 01 2014
Oncothyreon Reports First Quarter 2014 Financial Results May 01 2014
Q1 2014 Oncothyreon Inc. Earnings Release - After Market Close May 01 2014
As Investors Laud Combination Therapies, Oncothyreon's Pipeline Could Come Into Focus Apr 24 2014
Oncothyreon Announces First Quarter 2014 Financial Results Conference Call Apr 24 2014
Oncothyreon Announces First Quarter 2014 Financial Results Conference Call Apr 24 2014
Merck KGaA Starts Study on Tecemotide Apr 08 2014
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with... Apr 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide